---
schema_version: "secwatch.filing_event.v1"
accession: "0001398733-26-000020"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:28:11.699132+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aquestive Therapeutics appoints new CLO/ CCO; Braender steps down as CLO

## Summary
- Lori Braender steps down as CLO and CCO effective April 2, 2026; remains Corporate Secretary.
- Thomas Zalewski appointed CLO and CCO effective April 2, 2026; former Partner at Day Pitney.
- Zalewski receives inducement grant of 100k RSUs and 75k options, vesting over 3 years.
- Braender eligible for severance payments and accelerated vesting under separation agreement.

## SEC filing metadata
- accession: 0001398733-26-000020
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000020/0001398733-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000020/aqst-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001398733-26-000020
- JSON: https://secwatch.observer/filing/0001398733-26-000020.json
- Plain text: https://secwatch.observer/filing/0001398733-26-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.